$aTyr Pharma (LIFE.US)$ Management highlighted plans to laun...

Management highlighted plans to launch the ATYR1923 PH3 trial in pulmonary sarcoidosis in 2022. The company will also present additional preclinical data from ATYR2810 at SITC 2021 tomorrow and plans to move ATYR2810 into clinical trials next year. Recent attention has focused on the ph3 trial design conducted after the company's meeting with the FDA.